


## WE CLAIM:

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of Claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

3. A method for selectively increasing activation of the 5-HT<sub>2C</sub> receptor in mammals, comprising administering to a mammal in need of such activation an effective amount of a compound of Claim 1.

4. The method of Claim 3, where the mammal is human.

5. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

6. The method of Claim 5, where the mammal is human.

7. A method for the treatment of obsessive/compulsive disorder in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

8. The method of Claim 7, where the mammal is human.

9. A method for the treatment of depression in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

5

10. The method of Claim 9, where the mammal is human.

11. A method for the treatment of anxiety in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

10

12. The method of Claim 11, where the mammal is human.

13. A compound according to Claim 1 for use as a pharmaceutical.

15

14. A compound according to Claim 1 for use in selectively activating 5-HT<sub>2C</sub> receptors in a mammal.

15. A compound according to Claim 1 for use in the treatment of a 5-HT<sub>2C</sub> mediated disorder, where the disorder is obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, or hypogonadism.

20

16. A compound according to Claim 1 for use in the treatment of a 5-HT<sub>2C</sub> mediated disorder, where the disorder is obesity, obsessive/compulsive disorder, anxiety, or depression.

25

17. A compound according to Claim 1 for use in the treatment of obesity in mammals.

30

18. A compound according Claim 1 for use in the treatment of obsessive/compulsive disorder in mammals.

19. A compound according to Claim 1 for use in the treatment of depression in mammals.

5 20. A compound according to Claim 1 for use in the treatment of anxiety in mammals.

21. A compound according to any one of Claims 14-20, where the mammal is a human.

10 22. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of a 5-HT<sub>2C</sub> mediated disorder, where the disorder is obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism.

15 23. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of a 5-HT<sub>2C</sub> mediated disorder, where the disorder is obesity, obsessive/compulsive disorders, anxiety, or depression.

20 24. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of obesity in mammals.

25 25. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of obsessive/compulsive disorder in mammals.

26. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of depression in mammals.

30 27. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of anxiety in mammals.

28. The use according to any one of Claims 22-27, where the mammal is a human.

29. A pharmaceutical composition adapted for the treatment of obesity  
5 comprising a compound according to Claim 1 in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents therefore.

30. A pharmaceutical composition adapted for the treatment of  
obsessive/compulsive disorders comprising a compound according to Claim 1 in  
10 combination with one or more pharmaceutically acceptable excipients, carriers, or diluents therefore.

31. A pharmaceutical composition adapted for the treatment of depression  
comprising a compound according to Claim 1 in combination with one or more  
15 pharmaceutically acceptable excipients, carriers, or diluents therefore.

32. A pharmaceutical composition adapted for the treatment of anxiety  
comprising a compound according to Claim 1 in combination with one or more  
pharmaceutically acceptable excipients, carriers, or diluents therefore.  
20